###begin article-title 0
###xml 82 91 82 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a multifunctional secreted protein with pleiotropic actions, including the inhibition of matrix metalloproteinases (MMPs), cell death/survival and growth promoting activities. After inflammatory challenge, the levels of TIMP-1 are highly and selectively upregulated in astrocytes among glial cells, but little is know about its role in these neural cells. We investigated the influence of TIMP-1 null mutation in the reactivity of cultured astrocytes to pro-inflammatory stimuli with TNF-alpha and anti-Fas antibody.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 447 448 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
When compared to WT, mutant astrocytes displayed an overall increased constitutive gelatinase expression and were less responsive to Fas-mediated upregulation of MMP-9, of monocyte chemoattractant protein-1 (MCP-1) and of intercellular cell adhesion molecule-1 (ICAM-1), all markers of astrocyte inflammatory response. In contrast, TNF-alpha treatment induced all these factors similarly regardless of the astrocyte genotype. The incorporation of 3H-thymidin, a marker of cell proliferation, increased in wild-type (WT) astrocytes after treatment with anti-Fas antibody or recombinant TIMP-1 but not in mutant astrocytes. Finally, lymphocyte chemotaxis was differentially regulated by TNF-alpha in WT and TIMP-1 deficient astrocytes.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
We provide evidence that the alteration of the MMP/TIMP balance in astrocytes influences their reactivity to pro-inflammatory stimuli and that Fas activation modulates the expression of members of the MMP/TIMP axis. We hypothesise that the Fas/FasL transduction pathway and the MMP/TIMP system interact in astrocytes to modulate their inflammatory response to environmental stimuli.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 974 975 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1185 1186 1185 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1305 1306 1305 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1330 1331 1330 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1706 1707 1702 1703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1708 1710 1704 1706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1718 1720 1714 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1778 1780 1774 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1920 1922 1916 1918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 2177 2179 2169 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 2180 2182 2172 2174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 2235 2237 2227 2229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2238 2240 2230 2232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2304 2306 2296 2298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 2307 2309 2299 2301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2466 2468 2454 2456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2478 2480 2466 2468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 2490 2492 2478 2480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 2493 2495 2481 2483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 2506 2508 2494 2496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1075 1078 <span type="species:ncbi:10116">rat</span>
Injury in the central nervous system (CNS) is generally accompanied by an inflammatory reaction that involves mainly microglia and astrocytes. The latter are the most abundant cells in the CNS and their contribution to the pathological outcome is still a matter of debate. In response to injury, cytokines and chemokines trigger astrocyte proliferation and migration into the lesioned area where astrocytes contribute to the formation of the glial scar that inhibits axonal regeneration in the CNS [1]. Characteristic features of reactive astrocytes are morphological changes with cell body hypertrophy and increased expression of a number of proteins absent or weakly expressed in their resting state. Among these proteins, the MMPs and the TIMPs are highly upregulated in reactive astrocytes. TIMP-1 is a 31 kDa multifunctional secreted glycoprotein that possesses, in addition to its MMP inhibitor activity, growth promoting activities in a number of non neural cells [2-4]. We first demonstrated that TIMP-1 is massively and sequentially upregulated in cortical areas of rat brain after kainate-induced seizures, first in resistant neurons and subsequently in reactive astrocytes [5]. Selective TIMP-1 upregulation in astrocytes has also been reported after experimental autoimmune encephalomyelitis [6] or cerebral ischemia [7]. Interestingly, none of the aforementioned studies reported TIMP-1 expression in reactive microglial cells, highlighting the possibility of a specific role for TIMP-1 in astrocytes among glial cells. In cultured astrocytes, TIMP-1 is induced in response to a number of pro-inflammatory stimuli, including cytokines activated in the injured brain such as TNF-alpha or IL-1 [8-10], LPS [11] or after transient exposure to activated T lymphocytes [12]. Nevertheless, the effects of TIMP-1 in astrocytes are still largely unknown. We thus investigated the influence of TIMP-1 null mutation [13] on the response of cultured astrocytes to two cytokines of the TNF superfamily know to be induced in similar physiopathological conditions than TIMP-1. Notably, TNF-alpha and the Fas/FasL system are known to be death molecules for different cell types [14-16], but act as pro-inflammatory agents in astrocytes [17-20] the latter being resistant to Fas mediated cytotoxic effects [21-23]. In addition, it is known MMPs may regulate the activity of the TNF and Fas systems by proteolytic cleavage of some of their members, including TNF-alpha [24], TNF-R [25], Fas-L [26,27] and Fas [28].
###end p 9
###begin p 10
We provide evidence that the absence of TIMP-1 prevents the induction of MMP-9 and of inflammatory markers such as ICAM-1 or MCP-1 after Fas activation and that the mutant astrocytes proliferate less than the wild type in response to cytokines and to TIMP-1. TIMP-1 null mutation is also accompanied by an increased constitutive expression of gelatinases, mainly MMP-2. Altogether, these data indicate that the absence of TIMP-1 specifically attenuates the inflammatory response of astrocytes triggered by Fas but not by TNF-alpha and suggest that the MMP/TIMP balance is an important determinant in the pro-inflammatory effects of some members of the TNF family.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
Characterisation of astrocyte cultures
###end title 12
###begin p 13
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1048 1050 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1081 1083 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1084 1086 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
Astrocyte cultures were characterised as being greater than 95% pure by counting GFAP positive cells over the total number of cells stained by Hoechts # 33258. Microglial cells stained with F4/80 constituted the majority of GFAP negative cells (Fig. 1A). We confirmed by western blot that WT astrocytes constitutively expressed TIMP-1 and that the protein was absent in astrocytes from KO mice (Fig. 1B). As shown in Fig. 1C, no morphological differences were observed between astrocytes from WT or KO mice and the density of confluent cells was equivalent. This observation was supported by the finding that the MTT levels were identical in untreated WT and TIMP-1 KO cultures. Parallel experiments using propidium iodide as a cell death marker showed no differences in the constitutive cell death of untreated astrocytes (2-3%) between WT and mutant mice (results not shown). We found a mild reduction (16%) in mitochondrial activity by the test MTT only in WT astrocytes treated by TNF-alpha and no effect after anti-Fas antibody exposure (Fig. 1D). We confirmed previous data [21-23] demonstrating the absence of anti-Fas toxicity in astrocytes.
###end p 13
###begin title 14
TIMP-1 null mutation causes altered expression of MMP-2 and MMP-9
###end title 14
###begin p 15
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1190 1192 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1537 1539 1525 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
It is widely accepted that astrocytes express soluble MMP-2 and 9 (also known as gelatinases A and B, respectively) and TIMP-1. As TIMP-1 is the preferential inhibitor of MMP-9 and a good inhibitor of MMP-2, we used gel zymography to evaluate whether TIMP-1 depletion would influence the expression of both proteinases in the supernatants of WT and KO cultures after treatments. In control cultures, gel zymography (Fig. 2A) revealed the expected MMP-9 94 kDa band, and a predominant band at 63 kDa and a weaker band at 68 kDa, both of them coherent with expected molecular weights for MMP-2 active forms. We also detected a conspicuous band at 130 kDa. The constitutive levels of MMP-2 were more than twice the levels of MMP-9 in both WT and mutant astrocytes. TIMP-1 null mutation had no significant effect on constitutive MMP-9 expression, but increased the baseline levels of MMP-2 by 60%, as compared with WT astrocytes (Fig. 2C). In the latter, TNF-alpha and Fas activation significantly increased MMP-9 expression (80% and 110%, respectively). In the KO astrocytes, MMP-9 levels were upregulated only after exposure to TNF-alpha, while Fas activation had no significant effect (Fig. 2B). Treatments did not change the levels of MMP-2 except the anti-Fas antibody which reduced MMP-2 levels in KO astrocytes. When considering the total pool of gelatinases detected by gel zymography, we found that its constitutive level was higher in the KO astrocytes and increased with TNF-alpha and anti-Fas antibody in the WT astrocytes (Fig. 2D). Phenanthroline and BB-3103 abolished gelatinase activity, indicating that it was generated by metalloproteinases (not shown).
###end p 15
###begin title 16
ICAM-1 and MCP-1 are differentially induced in WT and TIMP-1 KO astrocytes
###end title 16
###begin p 17
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 694 695 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 942 943 938 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1052 1053 1044 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1144 1148 <span type="species:ncbi:10090">mice</span>
Astrocytes are the most abundant cells of the brain and express cytokines and adhesion molecules involved in different phases of neuroinflammation, including leukocyte recruitment in the CNS. Among these proteins, ICAM-1 and MCP-1 are strongly up-regulated during neuroinflammation, and preferentially in astrocytes [29-32]. Accordingly, both proteins are considered as markers of inflammatory response. In addition, the activities of ICAM-1 and MCP-1 are modulated by metalloproteinases [33,34]. For these reasons we examined whether the imbalance in the MMP/TIMP ratio observed in the mutant cultures would affect the levels of ICAM-1 and MCP-1 in astrocytes. As illustrated in figures 3 and 4, we found no differences in the constitutive expression of membrane bound ICAM-1 or release of MCP-1 between WT and KO cultures. However, exposure to TNF-alpha increased ICAM-1 levels in both WT and KO cultures (120% and 80%, respectively) (Fig. 3). An even higher upregulation of MCP-1 levels was observed after TNF-alpha in WT (215%) and KO (310%) (Fig. 4). In contrast, Fas activation upregulated ICAM-1 (70%) and MCP-1 (150%) levels only in WT mice, but not in TIMP-1 deficient astrocytes.
###end p 17
###begin title 18
KO astrocytes proliferate less than WT astrocytes in response to TNF-alpha and anti-Fas
###end title 18
###begin p 19
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 370 371 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 601 602 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 695 696 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Since cell proliferation is a hallmark of glial response to neuroinflammatory challenge, we measured the incorporation of 3H-thymidin, as an index of proliferation, into first passage synchronised astrocytes in response to cytokines and mrTIMP-1 (Fig. 5). We show that mrTIMP-1 induced the highest increase (200%) in proliferation of WT cells. Even though the levels of 3H-thymidin uptake in KO astrocytes treated with TIMP-1 were equivalent to those of WT astrocytes, statistical significance with respect to the untreated KO control was not reached, possibly because of a high level of constitutive 3H-thymidin incorporation in the mutant astrocytes. TNF-alpha did not significantly stimulate 3H-thymidin uptake in WT and KO astrocytes, unlike anti-Fas antibody that induced a significant 40% increase in WT but not in KO astrocytes.
###end p 19
###begin title 20
Effect of WT and KO astrocytes on lymphocyte recruitment
###end title 20
###begin p 21
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 429 430 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
MCP-1 is one of the main chemokines involved in the chemoattraction of monocytes and lymphocytes under inflammatory conditions [35,36]. We investigated whether WT astrocytes showing a dramatic upregulation of MCP-1 after exposure to TNF-alpha or anti-Fas antibody, would differentially affect lymphocyte migration as compared with KO astrocytes whose levels of MCP-1 were unaltered by anti-Fas antibody treatment. The data (Fig. 6) show that astrocytes alone increased by 300% the number of migrating lymphocytes regardless of the genotype. Moreover, in the absence of astrocytes, anti-Fas antibody alone was sufficient to significantly increase (200%) lymphocyte migration. However, the incubation of astrocytes with TNF-alpha increased the chemotaxis of lymphocytes, in particular in the KO astrocytes. In contrast, no effect of anti-Fas antibody was observed in WT or KO astrocytes as compared to their controls.
###end p 21
###begin title 22
Discussion
###end title 22
###begin p 23
###xml 534 538 <span type="species:ncbi:10090">mice</span>
The present report shows that TIMP-1 null mutation attenuates the inflammatory response of astrocytes to Fas activation. We show that TIMP-1 null mutation is associated with a higher constitutive MMP-2 expression, and that Fas activation fails to induce MMP-9, ICAM-1 and MCP-1 expression in KO astrocytes as it is the case in WT astrocytes. Moreover, KO astrocytes proliferate less than WT in response to anti-Fas and mrTIMP-1, whereas recruitment of lymphocytes is significantly induced only by TNF-alpha-treated astrocytes from KO mice.
###end p 23
###begin p 24
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 827 829 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1149 1151 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1152 1154 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1186 1188 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1320 1322 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1964 1966 1949 1951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1967 1969 1952 1954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 2098 2100 2083 2085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 2119 2121 2104 2106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 1142 1147 <span type="species:ncbi:9606">human</span>
###xml 1160 1165 <span type="species:ncbi:10090">mouse</span>
###xml 1252 1257 <span type="species:ncbi:10090">mouse</span>
###xml 1304 1307 <span type="species:ncbi:10116">rat</span>
The constitutive expression of gelatinases in general, and MMP-2 in particular, is higher in KO than in WT astrocytes, suggesting that in the absence of TIMP-1, the baseline regulation of one of its main targets is altered. The overall increase in gelatinase expression along with the absence of TIMP-1-mediated inhibition of MMPs in mutant astrocytes presumably increases MMP activity. As demonstrated previously in other cell types [37] and in brains from TIMP-1 KO mice [38], we assume that TIMP-1 deficiency is not compensated by the overexpression of other TIMPs, at least at the mRNA level. Our data showing a weak decrease of the mitochondrial activity after TNF-alpha exposure could be interpreted as a mild cytotoxic effect in agreement with studies reporting <20% astrocyte cell death after exposure to the cytokine [39]. We can not rule out the possibility that the absence of cell death under TNF treatment in KO astrocytes may be actually related to a relatively higher baseline proliferative potential in these cultures. We also show that astrocytes are resistant to Fas-mediated cell death in keeping with previous findings in human [21,22] and mouse astrocyte cultures [23]. Moreover, the TNF-alpha mediated induction of MMP-9 found in mouse astrocytes was equivalent to that reported in rat astrocytes [40]. However, this is the first report demonstrating that the activation of Fas stimulates MMP-9 release by astrocytes. Together, these data support the idea that the activation of receptors of the TNF superfamily triggers inflammatory rather than death signals in astrocytes, and that MMP-9 could act as an inflammatory factor downstream of Fas activation. It is likely that the induced expression of MMP-9 amplifies the inflammatory cascade initiated by cytokines through mechanisms involving the proteolytic activation of latent forms of cytokines. MMP-9 can proteolytically convert latent forms of TNF-alpha and IL-1beta into active forms [24,41]. The presumably pro-inflammatory role of MMP-9 in astrocytes does not preclude its cytotoxic action demonstrated for cortical [42] and hippocampal [43] neurons in excitotoxic/inflammatory paradigms.
###end p 24
###begin p 25
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
The most striking finding of the present study was the reduced response displayed by TIMP-1 deficient astrocytes to anti-Fas antibody, in clear contrast with the response of their WT counterparts. Failure in inducing MMP-9, ICAM-1 and MCP-1 strongly suggests that the absence of TIMP-1 disturbs the Fas signal transduction pathway. TIMPs are considered as multifunctional proteins with anti-MMP, cell-death/survival, and growth promoting activities [44]. Some of the mechanisms underlying these actions are related with the ability of TIMPs to prevent proteolytic processing of membrane receptors, such as death receptors of the TNF superfamily. It has been suggested that the stabilisation of Fas by endogenous (TIMP-1 and TIMP-3) and synthetic MMP inhibitors is responsible for increased sensitivity to apoptosis of various cell types, including Dev neural precursors cells [45] or cancer cells [46]. Recently, MMP-7 has been identified as a sheddase of Fas that induces apoptosis resistance in tumour cells [47]. Considering that astrocytes express high constitutive levels of Fas [23] and that astrocytes deficient for TIMP-1 likely have an increased proteolytic activity, we hypothesise that constitutive cleavage of Fas may indeed reduce the levels of Fas at the membrane, and consequently hamper astrocyte reactivity to anti-Fas antibody treatment. MMP-2, whose levels are constitutively increased in TIMP-1 KO astrocytes, decreased however after anti-Fas treatment. It is tempting to speculate that elevated levels of MMP-2 contribute directly or indirectly to Fas cleavage in normal conditions. The exposure of cells to a Fas-L-like factor would favour the downregulation of MMP-2 in an attempt to re-establish the levels of the receptor. Nevertheless, the role of MMP-2 as a Fas sheddase has not been demonstrated yet.
###end p 25
###begin p 26
###xml 566 568 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 569 570 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 660 662 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1031 1032 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1898 1899 1894 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1900 1901 1896 1897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1996 2004 1992 2000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2036 2038 2032 2034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
Together, these data bring support to the hypothesis that TIMP-1 exerts a pro-inflammatory effect by facilitating astrocyte reactivity through the regulation of the MMP/TIMP balance. Astrocyte proliferation is a hallmark of reactivity in inflammatory settings. For the first time, we demonstrate that TIMP-1 induces astrocyte proliferation and this effect is stronger than the effects mediated by TNF-alpha or anti-Fas antibody. Our data support the idea that TIMP-1 exerts a control on cell growth, as previously suggested by other authors in different cell types [48,4]. Moreover, it has been shown that TIMP-1 accumulates in the nucleus of some cell types [49] and it has been suggested that it could regulate the cell cycle via a MMP-independent mechanism. This idea is reinforced by the finding in our laboratory that mrTIMP-1 increases by 2-fold the number of astrocytes in a mixed neuronal-astrocyte culture, and that this effect is not mimicked by broad spectrum MMP inhibitors (unpublished results). The baseline level of 3H-thymidin uptake in KO astrocytes was higher than in the WT. Perhaps, for this reason, a pro-inflammatory stimulus with cytokines or TIMP-1 did not induce further significant increases in KO astrocyte proliferation. It is possible that a low constitutive expression of TIMP-1 maintains astrocytes in a resting "low proliferative" state that reacts promptly to a pro-inflammatory stimulus. On the contrary, the chronic absence of TIMP-1 may cause a state of permanent mild "reactivity" or "inflammatory status" that increases the response threshold for new exogenous pro-inflammatory stimuli. From the above, it follows that TIMP-1 might actually act as a homeostatic factor for astrocytes in the resting state, and as a pro-inflammatory factor in stressful conditions, notably in seizing and ischemic brains, where early and massive induction of TIMP-1 in neurons [5,7] precede astrocyte reactivity. Pro-inflammatory effects of TIMP-1 have also been suggested in in vivo models of rheumatoid arthritis [50].
###end p 26
###begin p 27
###xml 897 899 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1005 1007 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
We expected that mutant astrocytes resistant to Fas-mediated induction of MCP-1 would attract lymphocytes less efficiently than WT astrocytes displaying a strong upregulation of MCP-1 in the same treatment conditions. The fact that untreated astrocytes did increase by 300% the number of migrating lymphocytes clearly indicates that these glial cells have a strong chemoattractant capacity in culture conditions, perhaps in part because of their constitutive MCP-1 release. Moreover, the finding that anti-Fas antibody alone caused a 200% increase in lymphocyte migration reveals also a potent chemotactic effect of FasL, independently of its cellular source, in clear contrast with the absence of chemotactic effects of TNF-alpha alone. These data are coherent with previous reports demonstrating that soluble FasL is chemotactic for neutrophils and that an anti-Fas antibody mimics this effect [51]. In addition, it has been shown that Fas activation stimulates motility in the absence of cytotoxicity [52]. In our experimental model, it its possible that the threshold of stimulation necessary for Fas/astrocyte-mediated lymphocyte migration is already achieved by the individual components of the tandem.
###end p 27
###begin p 28
###xml 578 580 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 768 770 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1038 1040 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1117 1119 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1313 1315 1305 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1247 1252 <span type="species:ncbi:10090">mouse</span>
###xml 1611 1615 <span type="species:ncbi:10090">mice</span>
The strong chemoattractant effect of TIMP-1 deficient astrocytes when exposed to TNF-alpha, cannot be interpreted on the basis of the MCP-1 release, since the latter was equivalent in both WT and TIMP-1 deficient cells. This finding suggests that MCP-1 alone is not sufficient to critically influence the chemoattraction of lymphocytes. The activity of MCPs is regulated by MMP-mediated proteolytic processing, resulting in new bioactive truncated proteins with antagonist effects on leukocyte migration. In this scenario, MMPs would indirectly act as anti-inflammatory agents [34]. However, we cannot speculate on a possible interaction between gelatinases (MMP-2 and MMP-9) and MCP-1 since the latter has been reported to be specifically cleaved by MMP-1 and MMP-3 [34]. An alternative way of interpreting the increased lymphocyte migration in the TIMP-1 deficient astrocytes exposed to TNF-alpha, refers to the possible regulation of ICAM-1 by gelatinases at the surface of astrocytes; MMPs cleave membrane-bound ICAM-1 in astrocytes [53], and MMP-9 appears to be the key enzyme processing ICAM-1 in tumour cells [54]. Soluble ICAM-1 (sICAM-1) generated by this cleavage has been reported to induce macrophage inflammatory protein-2 (MIP-2) in mouse astrocytes and subsequently stimulate leucocytes migration [55]. A lower TIMP-1 inhibitory capacity in the mutant astrocytes, along with an increased gelatinase activity, would favour sICAM-1 proteolytic generation and possibly lymphocyte migration after TNF-alpha treatment. This idea is coherent with the overall lower ICAM-1 levels found in the TIMP-1 KO mice.
###end p 28
###begin title 29
Conclusion
###end title 29
###begin p 30
In summary, the present data provide evidence linking the MMP/TIMP balance to the reactive response of astrocytes following pro-inflammatory stimuli. The control of astrocyte reactivity by the MMP/TIMP axis affects in a particular way the Fas/FasL pathway, and suggests that in astrocytes, the outcome of the neuroinflammatory status in pathological situations may involve the mutual regulation of these two molecular systems. We can not exclude that other MMP substrates (ICAM, MCPs) are also affected by changes in the proteolytic balance. We are just starting to unveil the importance that the proteolytic modification of bioactive factors may have in the control of cell behaviour and intercellular communication. The study of the MMP/TIMP roles in neural cells and of the mechanisms whereby these proteinases and inhibitors exert the control of cell behaviour is a challenging question that needs further investigation.
###end p 30
###begin title 31
Methods
###end title 31
###begin title 32
Animals
###end title 32
###begin p 33
All experimental procedures were performed in compliance with our institutional guidelines after obtaining the authorisation of the Laboratory Animal Committee of the Medical Faculty.
###end p 33
###begin p 34
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Timp1 </italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
TIMP-1 deficient mice (Sv-129) were generated by homologous recombination and functional TIMP-1 protein was detected in WT cells, but not in co-isogenic cell lines carrying the mutation in Timp1 [13]. Genetically modified (KO) and WT mice have an identical genetic background. Genomic DNA was extracted from the tail tips of mice to determine their genotype by PCR.
###end p 34
###begin title 35
Astrocyte cultures
###end title 35
###begin p 36
###xml 305 307 305 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 355 357 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 622 630 615 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1142 1144 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:9913">calf</span>
###xml 808 814 <span type="species:ncbi:9913">bovine</span>
###xml 970 975 <span type="species:ncbi:10090">mouse</span>
Astrocytes were obtained from the brains of 2-day-old mice. After removal of the meninges, the brains were dissociated into a single-cell suspension by trypsinisation and mechanical disruption. The cells were seeded on poly-L-lysine (Sigma St Louis, MO, USA) coated culture plates at the density of 4 x 104 cells per cm2 and grown at 37degreesC in a 5% CO2 humidified atmosphere in Dulbecco's Modified Eagle Medium (DMEM) containing 10% foetal calf serum, 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 mug/ml) (all from InVitrogen, Carlsbad, CA, USA). The medium was replaced every 3 days. After 8-10 days in vitro, the medium was changed for 24 h into serum free medium containing DMEM, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 mug/ml), 5 mug/ml insulin (Sigma,) and 0,05% bovine serum albumin (BSA - InVitrogen). Cells were then treated for 24 h with 10 ng/ml TNF-alpha (R&D Systems, Minneapolis, MN, USA) and 0.5 mug/ml hamster anti-mouse Fas antibody (Clone Jo2, BD Pharmingen, San Jose, CA, USA) which mimics the effects of FasL, activates Fas and stimulates pro-inflammatory responses from astrocytes [23].
###end p 36
###begin title 37
Western blot
###end title 37
###begin p 38
###xml 458 462 <span type="species:ncbi:9925">goat</span>
###xml 468 473 <span type="species:ncbi:10090">mouse</span>
###xml 535 539 <span type="species:ncbi:9925">goat</span>
###xml 725 730 <span type="species:ncbi:10090">mouse</span>
Protein concentration of culture supernatants was normalised using the Lowry method (DC-Protein assay, Bio-Rad, Hercules, CA, USA). Using a Bio-Rad MiniBlot system, equal amounts of protein were subjected to 8.5% sodium dodecyl sulphate - polyacrylamide gels electrophoresis (SDS-PAGE), under reducing and denaturing conditions, and then transferred to PVDF immunoblotting membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). TIMP-1 was detected by a goat anti-mouse TIMP-1 antibody (R&D Systems), followed by biotinylated anti-goat IgG and streptavidin-peroxidase (both from Jackson ImmunoResearch, West Grove, PA, USA), and then visualised by chemiluminescence reaction using the ECL system (Amersham). Glycosylated mouse recombinant (mr) TIMP-1 (R&D Systems) was used as a control in each gel.
###end p 38
###begin title 39
Astrocyte and microglia staining
###end title 39
###begin p 40
###xml 549 553 549 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 584 588 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 241 245 <span type="species:ncbi:9925">goat</span>
###xml 285 291 <span type="species:ncbi:9986">rabbit</span>
###xml 297 300 <span type="species:ncbi:9913">cow</span>
###xml 344 347 <span type="species:ncbi:10116">rat</span>
###xml 353 358 <span type="species:ncbi:10090">mouse</span>
###xml 562 568 <span type="species:ncbi:9986">rabbit</span>
###xml 597 600 <span type="species:ncbi:10116">rat</span>
In order to charaterise the cell type composition of our cultures we used glial fibrillary acidic protein (GFAP) as an astrocytic marker and F4/80 as a microglial marker. Briefly, cells were preincubated with 0.1% triton X-100 and 5% normal goat serum (NGS) for 30 min, incubated with rabbit anti-cow GFAP (DAKO, Glostrup, Denmark) (1/500) and rat anti-mouse F4/80 (Serotec, Kidlington, Oxford, UK) (1/500) antibodies diluted in PBS containing 0.1% triton X-100 and 5% serum for 1 h. Cells were then rinsed in PBS, incubated for 1 h with Alexa Fluor(R) 594 anti-rabbit and Alexa Fluor(R) 488 anti-rat antibodies respectively (Molecular Probes, Eugene, OR, USA), rinsed in PBS, and the DNA intercalant Hoechts #33258 (Molecular Probes) was added during 5 min to label cell nuclei. Cells were then mounted in fluorescent mounting medium (DAKO), observed under a Nikon E800 upright microscope (Nikon Champigny-sur-Marne, France) equipped with epifluorescence, TRITC, FITC and DAPI filters, DXM 1200 camera and the LUCIA image analysis software.
###end p 40
###begin title 41
3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
###end title 41
###begin p 42
###xml 218 220 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
In order to test a possible cytotoxic effect of treatments, TNF-alpha and anti-Fas antibody were incubated for 24 h and cell death measured by the MTT (Sigma) assay that detects mitochondrial activity in living cells [56]. Results are expressed as the arbitrary units of optical density. The means +/- S.E.M. were obtained from triplicates within a single experiment and at least three independent experiments.
###end p 42
###begin title 43
Gel zymography
###end title 43
###begin p 44
###xml 277 278 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 479 482 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-2 </sup>
###xml 822 823 814 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0</italic>
Equal amounts of protein were subjected to 8.5% SDS-PAGE containing 0.5% gelatine (Sigma) in non-denaturing, non-reducing conditions. Gels were washed twice for 15 min in 2.5% Triton X-100 to remove SDS, and incubated at 37degreesC for 22 h in 100 mM Tris pH 7.4 and 15 mM CaCl2. Gels were then stained with 0.1% Coomassie blue R-250 (Bio-Rad) for 20 min and distained in 10% acetic acid until clear bands of gelatinolysis appeared on a dark background. Bacterial collagenase (10-2 U/ml, Sigma) was loaded in each gel as a control and used for normalisation. Gels were scanned and bands were quantified using GeneTools software. Each test was performed in triplicate within single experiments and means +/- S.E.M. were obtained from at least three independent experiments. Some zymogram gels were incubated with 1 mM 1,10-0-phenanthroline (Sigma) or BB-3103, two broad spectrum inhibitors of metalloproteinases.
###end p 44
###begin title 45
Flow cytometry
###end title 45
###begin p 46
###xml 61 64 <span type="species:ncbi:10116">rat</span>
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
###xml 213 217 <span type="species:ncbi:9925">goat</span>
###xml 223 226 <span type="species:ncbi:10116">rat</span>
Astrocyte cultures were incubated on ice for 15 min with the rat anti-mouse ICAM-1 antibody purified from the supernatants of YN1 hybridoma cells (R&D Systems). After washes, cells were treated with FITC-labelled goat anti-rat IgG (Jackson ImmunoResearch) for 15 min in ice. Cells were washed, centrifuged and resuspended in PBS and 2% paraformaldehyde. A control without anti-ICAM-1 antibody served as blank to normalise the mean of fluorescence. FACS analysis was performed on a FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA) using Cellquest Software (Becton Dickinson). The number of positive cells in each assay was standardised to 5000. Results were expressed in arbitrary units corresponding to the mean of fluorescence, and were obtained from at least three independent experiments.
###end p 46
###begin title 47
Enzyme linked immuno-adsorbent assay for MCP-1
###end title 47
###begin p 48
###xml 183 188 <span type="species:ncbi:10090">mouse</span>
###xml 230 241 <span type="species:ncbi:3704">horseradish</span>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
###xml 340 345 <span type="species:ncbi:10090">mouse</span>
MCP-1 expression in astrocyte supernatants was measured using an ELISA kit (BD Pharmingen) according to the manufacturer's instructions. Equal amounts of protein were added onto anti-mouse MCP-1 antibody-coated wells, detected by horseradish peroxydase-conjugated anti-mouse MCP-1 antibody and revealed with o-phenylenediamine. Recombinant mouse MCP-1 was used as control to determine the concentration of MCP-1 in the sample. Each test was performed in triplicate within single experiments and means +/- S.E.M. were obtained from at least three independent experiments.
###end p 48
###begin title 49
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Proliferation assay by 3H-thymidin incorporation
###end title 49
###begin p 50
###xml 16 24 16 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 145 147 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 367 368 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
After 8-10 days in vitro, astrocytes were trypsinised and reseeded in serum containing medium in 96-well flat-bottom plates, at the density of 104 cells per well. Twenty four hours after, the culture medium was replaced with serum-free medium for 24 h and cells were then treated with TNF-alpha, anti-Fas antibody or mrTIMP-1 in triplicate. Two days later, 1 muCi of 3H thymidin (Amersham Pharmacia Biotech) was added in each well. After 18 h, cells were harvested on filter mats, dried and counted using 1600TR liquid scintillation analyser (Pachard Instruments, Meriden, CT, USA). The results were expressed as total cpm. Each test was performed in triplicate within single experiments and means +/- S.E.M. were obtained from at least three independent experiments.
###end p 50
###begin title 51
Lymphocyte recruitment in transwell chambers
###end title 51
###begin p 52
###xml 203 205 199 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 217 219 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 694 696 685 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
We used a transwell system in order to evaluate the influence of astrocytes treated with TNF-alpha and anti-Fas antibody on lymphocyte migration. Lymphocytes were obtained from spleen, cultured at 4 x 104 cells per cm2 and activated with recombinant IL-2 (InVitrogen) and with the supernatant of splenic cells stimulated with concanavalin A (Sigma). Astrocytes were seeded in the lower part of the well, as described above, and treated for 24 h with TNF-alpha or anti-Fas antibody in a serum free medium. Lymphocytes were labelled with 10 muM CFSE (5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (5(6)-CFDA, SE; CFSE - Molecular Probes) by a 15 min incubation. Lymphocytes (1.5 x 104 per well) were then seeded on the upper part of 3 mum pore clear polycarbonate transwells (Costar, Cambridge, MA, USA) and allowed to migrate for 7 hours. The filters were then removed and photomicrographs of migrated lymphocytes in the lower well were taken using a Nikon TE300 inverted microscope equipped a FITC filter, and images were analysed using a DXM 1200 camera and the LUCIA image analysis software (Nikon). Wells without astrocytes in the lower part or astrocytes without treatment were used as controls. The number of labelled lymphocytes in the lower compartment was quantified using GenTools software (Syngene). Tests were performed in triplicate within single experiments and means +/- S.E.M. were obtained from three independent experiments.
###end p 52
###begin title 53
List of abbreviations
###end title 53
###begin p 54
CNS, central nervous system; ICAM-1, intercellular adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of MMP; TNF, Tumour Necrosis Factor.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
CO performed most of the assays and co-wrote the manuscript.
###end p 56
###begin p 57
RC participated to the lymphocyte recruitment assay.
###end p 57
###begin p 58
JB made substantial contributions to conception and design of experiments.
###end p 58
###begin p 59
###xml 16 31 <span type="species:ncbi:10090">transgenic mice</span>
PS provided the transgenic mice.
###end p 59
###begin p 60
MK contributed to design the project and revised the manuscript for important intellectual content.
###end p 60
###begin p 61
SR supervised the project and wrote the manuscript.
###end p 61
###begin p 62
All authors read and approved the final manuscript and its submission to BMC Neuroscience.
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
This work was supported by funding from CNRS, from the Faculty of Medicine of Marseilles (BQR) and from the Association pour la Recherche sur la Sclerose en Plaques (ARSEP). C.O. was granted a fellowship from "La Ligue Contre le Cancer". BB-3103 was provided by British Biotech Pharmaceuticals.
###end p 64
###begin article-title 65
The glial scar and central nervous system repair
###end article-title 65
###begin article-title 66
###xml 63 68 <span type="species:ncbi:9606">human</span>
Molecular characterization and expression of the gene encoding human erythroid-potentiating activity
###end article-title 66
###begin article-title 67
###xml 22 27 <span type="species:ncbi:9606">human</span>
Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases.
###end article-title 67
###begin article-title 68
Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum.
###end article-title 68
###begin article-title 69
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response
###end article-title 69
###begin article-title 70
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states
###end article-title 70
###begin article-title 71
Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia
###end article-title 71
###begin article-title 72
Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons
###end article-title 72
###begin article-title 73
Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines
###end article-title 73
###begin article-title 74
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia
###end article-title 74
###begin article-title 75
Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2)
###end article-title 75
###begin article-title 76
###xml 156 161 <span type="species:ncbi:9606">human</span>
T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease
###end article-title 76
###begin article-title 77
Targeted mutagenesis of TIMP-1 reveals that lung tumor invasion is influenced by TIMP-1 genotype of the tumor but not by that of the host
###end article-title 77
###begin article-title 78
Fas ligand-induced apoptosis
###end article-title 78
###begin article-title 79
Tumor necrosis factor receptor and Fas signaling mechanisms
###end article-title 79
###begin article-title 80
Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas
###end article-title 80
###begin article-title 81
###xml 59 64 <span type="species:ncbi:9606">human</span>
Caspase 8 expression and signaling in Fas injury-resistant human fetal astrocytes
###end article-title 81
###begin article-title 82
Signalling by CD95 and TNF receptors: not only life and death
###end article-title 82
###begin article-title 83
CD95-CD95L: can the brain learn from the immune system?
###end article-title 83
###begin article-title 84
A self-defence mechanism of astrocytes against Fas-mediated death involving interleukin-8 and CXCR2
###end article-title 84
###begin article-title 85
###xml 18 23 <span type="species:ncbi:9606">human</span>
Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity
###end article-title 85
###begin article-title 86
CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation?
###end article-title 86
###begin article-title 87
Differential regulation and function of Fas expression on glial cells
###end article-title 87
###begin article-title 88
Processing of tumour necrosis factor-alpha precursor by metalloproteinases
###end article-title 88
###begin article-title 89
Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis
###end article-title 89
###begin article-title 90
###xml 38 43 <span type="species:ncbi:9606">human</span>
Metalloproteinase-mediated release of human Fas ligand
###end article-title 90
###begin article-title 91
Downregulation of Fas ligand by shedding
###end article-title 91
###begin article-title 92
Shedding of Fas ectodomain that affects apoptosis of hepatocytes occurring in regenerative liver
###end article-title 92
###begin article-title 93
Adhesion molecule expression and regulation on cells of the central nervous system
###end article-title 93
###begin article-title 94
Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation
###end article-title 94
###begin article-title 95
TWEAK stimulation of astrocytes and the proinflammatory consequences
###end article-title 95
###begin article-title 96
Immune function of astrocytes
###end article-title 96
###begin article-title 97
Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease
###end article-title 97
###begin article-title 98
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo
###end article-title 98
###begin article-title 99
###xml 154 173 <span type="species:ncbi:1765">Mycobacterium bovis</span>
Role of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma delta T lymphocyte trafficking during inflammation induced by lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guerin
###end article-title 99
###begin article-title 100
Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS
###end article-title 100
###begin article-title 101
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Pattern of messenger ribonucleic acid expression of tissue inhibitors of metalloproteinases (TIMPs) during testicular maturation in male mice lacking a functional TIMP-1 gene
###end article-title 101
###begin article-title 102
Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Modulates Neuronal Death, Axonal Plasticity, and Learning and Memory
###end article-title 102
###begin article-title 103
Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNFalpha-induced apoptosis
###end article-title 103
###begin article-title 104
###xml 94 97 <span type="species:ncbi:10116">rat</span>
Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes
###end article-title 104
###begin article-title 105
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing
###end article-title 105
###begin article-title 106
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
###end article-title 106
###begin article-title 107
Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate
###end article-title 107
###begin article-title 108
Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications
###end article-title 108
###begin article-title 109
[Astrocytes, cells involved in neuro-immune interactions in the central nervous system]
###end article-title 109
###begin article-title 110
Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors
###end article-title 110
###begin article-title 111
Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells
###end article-title 111
###begin article-title 112
###xml 63 68 <span type="species:ncbi:9606">human</span>
Molecular characterization and expression of the gene encoding human erythroid-potentiating activity
###end article-title 112
###begin article-title 113
###xml 105 110 <span type="species:ncbi:9606">human</span>
Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts
###end article-title 113
###begin article-title 114
Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis
###end article-title 114
###begin article-title 115
Chemotactic activity of soluble Fas ligand against phagocytes
###end article-title 115
###begin article-title 116
CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells
###end article-title 116
###begin article-title 117
Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease
###end article-title 117
###begin article-title 118
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity
###end article-title 118
###begin article-title 119
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
The production of macrophage inflammatory protein-2 induced by soluble intercellular adhesion molecule-1 in mouse astrocytes is mediated by src tyrosine kinases and p42/44 mitogen-activated protein kinase
###end article-title 119
###begin article-title 120
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
###end article-title 120
###begin title 121
Figures and Tables
###end title 121
###begin p 122
###xml 40 43 40 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 365 368 365 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B. </bold>
###xml 546 549 546 549 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C. </bold>
###xml 682 685 682 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D. </bold>
###xml 933 934 929 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 441 446 <span type="species:ncbi:10090">mouse</span>
Characterisation of astrocyte cultures. A. Epifluorescence photomicrographs showing combined labelling with anti-GFAP and anti-F4/80 antibodies, and nuclear intercalant Hoechst. Astrocyte culture were charaterised as being greater than 95% pure by counting GFAP-positive cells and F4/80-positive cells (microglia) over the total number of cells stained by Hoechst. B. Expression of TIMP-1 in astrocytes was assessed by western blot; lane 1: mouse recombinant TIMP-1, lane 2: supernatant of WT astrocytes and lane 3: supernatant of KO astrocytes. C. Phase contrast photomicrographs of astrocyte cultures. No apparent morphological differences were seen between WT and KO astrocytes. D. Effect of treatments on cell viability. Only TNF-alpha treatment induced a mild cytotoxic effect on WT astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's t-test when comparing treatments to normalised values (* p < 0.05). Scale bar represents 50 mum.
###end p 122
###begin p 123
###xml 45 48 45 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 269 270 265 266 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 302 303 298 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 540 543 532 535 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D. </bold>
###xml 917 918 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Expression of MMP-9 and MMP-2 in astrocytes. A. Gelatine zymograms from culture supernatants of WT and KO astrocytes in control condition (lane 1) or after treatment with TNF-alpha (lane 2) and anti-Fas antibody (lane 3). Quantitative expression of the 94 kDa (MMP-9) (B) and the 63 kDa form of MMP-2 (C). Constitutive levels of MMP-2 in KO were higher than in WT astrocytes. MMP-9 was up-regulated by TNF-alpha in both strains of astrocytes. Fas activation significantly induced MMP-9 expression in WT astrocytes but not in KO astrocytes. D. Total gelatinase expression detected in gel zymography. The total gelatinase expression was higher in KO astrocytes as compared to WT astrocytes. TNF-alpha and anti-Fas treatments increased total gelatinase expression only in WT astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's t-test when comparing treatments to control cells within a given genotype (* p < 0.05) or KO vs WT cells ( p < 0.05).
###end p 123
###begin p 124
###xml 46 49 46 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 126 129 122 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B. </bold>
###xml 453 454 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
Expression of ICAM-1 in WT and KO astrocytes. A. Plots of flow cytometry after treatment with TNF-alpha or anti-Fas antibody. B. Quantification of ICAM-1 expression. ICAM-1 levels were up-regulated by TNF-alpha in astrocytes from WT and KO mice, whereas Fas activation increased ICAM-1 expression only in WT astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's t-test when comparing treatments to control cells (* p < 0.05).
###end p 124
###begin p 125
###xml 362 363 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
Release of MCP-1 by WT and KO astrocytes was measured in supernatants by ELISA. MCP-1 release was up-regulated by TNF-alpha in astrocytes from WT and KO mice, whereas Fas activation increased MCP-1 release only in WT astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's t-test when comparing treatments to control cells (* p < 0.05).
###end p 125
###begin p 126
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Astrocyte proliferation was estimated by measuring 3H-thymidin uptake, expressed in cpm. Note that constitutive uptake was higher in KO than in WT astrocytes. Both anti-Fas antibody and mrTIMP-1 increased proliferation of WT astrocytes but not of KO astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's t test when comparing treatments to control cells with the same genotype (* p < 0.05) or KO vs WT cells ( p < 0.05).
###end p 126
###begin p 127
###xml 144 145 144 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 177 178 177 178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 507 508 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
The effect of astrocytes on lymphocyte migration was assessed using Transwell chambers and was expressed by the total number of migrated cells (A) and as an index of migration (B). Note that anti-Fas treatment alone without astrocytes in the lower compartment induced lymphocyte migration. Only KO astrocytes treated with TNF-alpha induced significant lymphocyte migration. Values represent the mean +/- s.e.m. of at least three independent experiments. Statistical differences were determined by Student's t-test when comparing treatments to control cells (* p < 0.05) or astrocytes vs no astrocyte ( p < 0.05).
###end p 127

